[Objectives] Pitavastatin is theˆrst totally synthetic HMG-Co A reductase inhibitor in Japan that signiˆcantly reduces LDL cholesterol while raising HDL cholesterol. Clinical trial showed that pitavastatin has potent eŠects for LDL cholesterol lowering and is expected eŠectively to prevent atherosclerosis. To clarify the mechanism of reduction of atherosclerosis by pitavastatin, we examined the eŠect of pitavastatin on foam cell formation of RAW264.7 macrophages. [Methods & Results] Macrophages were cultured with pitavastatin for 24 h and exposed to oxidized LDL with pitavastatin for 3 days. Pitavastatin decreased the cellular cholesteryl ester content in a dose-dependent manner, and this eŠect was not via inhibition of HMG-CoA reductase because the 3-30 nM pitavastatin did not inhibit [ 14 C]cholesterol synthesis from [ 14 C]acetic acid and the eŠect was not in‰uenced by addition of mevalonic acid. Pitavastatin increased neutral cholesterol esterase (NCEase) activity and did not aŠect ACAT activity, and decreased the expression of CD36 and ABCA1 mRNA. The mechanism of the increase of NCEase activity was that pitavastatin directly modiˆed the substrate state, which was cholesterol oleate emulsiˆed with lecithin.

